Charles Broome
Orthopaedic Surgery · San Antonio, TXNPI 1720129992
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,599 of the $17,418 with a category attached, or 72.3%. Smith+Nephew accounts for 79.7% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $7,664 and has fallen 96.3% since, to $280 in 2025.
Across 68 payments — averaging $256.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$14K
- Heron Therapeutics, Inc.$3K
- Stryker$129
- Alafair Biosciences, Inc.$85
- Anika Therapeutics, Inc.$38
- Pfizer$29
- plus $231 from 12 others
Across 162 payments — averaging $23,282 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$2.5M
- Heron Therapeutics, Inc.$1M
- Linvatec Corporation$132K
- Davol Inc.$123K
- Conmed Corporation$2K
What the payments were for
- Consulting fees$2,62515%
- Speaking & faculty fees$12,59972%
- Travel & lodging$6554%
- Food & beverage$1,5409%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 22 | $13,883 |
| Heron Therapeutics, Inc. | 24 | $3,023 |
| Stryker | 5 | $129 |
| Alafair Biosciences, Inc. | 1 | $85 |
| Anika Therapeutics, Inc. | 1 | $38 |
| Pfizer | 2 | $29 |
| Vertex | 1 | $28 |
| Convatec Inc. | 2 | $28 |
| Medinc Of Texas | 1 | $22 |
| DJO, LLC | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Si-bone, Inc. | 1 | $21 |
| Fidia Pharma USA Inc. | 1 | $20 |
| Bioventus LLC | 1 | $16 |
| Radius Health, Inc. | 1 | $15 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Heraeus Medical, LLC. | 1 | $13 |
| Vericel Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Journey II$8,535
- Anthology$7,566
- POLARSTEM$6,479
- Oxinium Hips$5,906
- POLARCUP$5,906
- R3$5,906
- REAL INTELLIGENCE$4,268
- Zynrelef$2,625
- Engage Partial Knee System$2,608
- RI.HIP NAVIGATION$2,608
- Journey II BCS$2,233
- BIRMINGHAM HIP$1,660
- Journey II CR$1,660
- JOURNEY II UK$1,660
- K-15 PORK$147
How this compares
$17,418 in reported general payments places this provider in the 75th percentile of 1,337 orthopaedic surgery providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 48 | $1,859 |
| Tranexamic Acid | 17 | $305 |
| Tramadol Hcl | 47 | $176 |
| Gabapentin | 26 | $96 |
| Cefadroxil | 17 | $93 |
| Oxycodone Hcl | 18 | $90 |
| Meloxicam | 26 | $75 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in San Antonio
- Stephen BurkhartSan Antonio$185.3M
- Michael WirthSan Antonio$4.5M
- Ravi KariaSan Antonio$1.1M
- Charles RockwoodSan Antonio$975K
- Christopher ChaputSan Antonio$959K
- Frank ButtacavoliSan Antonio$866K
- Robert HartzlerSan Antonio$654K
- Bernard MorreySan Antonio$639K
- Animesh AgarwalSan Antonio$408K
- Ralph GarzaSan Antonio$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.